Schwabe Stefan K.F. 4
4 · SUPERNUS PHARMACEUTICALS INC · Filed Jun 19, 2018
Insider Transaction Report
Form 4
Schwabe Stefan K.F.
Executive Vice President R&D
Transactions
- Exercise/Conversion
Employee Stock Option (Right to Buy)
2018-06-18−20,000→ 0 totalExercise: $7.90Exp: 2023-02-05→ Common Stock (20,000 underlying) - Exercise/Conversion
Common Stock
2018-06-18$7.90/sh+20,000$158,000→ 21,967 total - Exercise/Conversion
Employee Stock Option (Right to Buy)
2018-06-18−40,000→ 0 totalExercise: $9.24Exp: 2024-01-21→ Common Stock (40,000 underlying) - Sale
Common Stock
2018-06-18$54.39/sh−60,000$3,263,352→ 1,967 total - Exercise/Conversion
Common Stock
2018-06-18$9.24/sh+40,000$369,600→ 61,967 total
Footnotes (4)
- [F1]Transaction made pursuant to a Rule 10b5-1 trading plan adopted May 17, 2018.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.000 to $54.900, inclusive. The reporting person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
- [F3]The option became exercisable in four equal installments beginning on February 5, 2014, which was the first anniversary of the date on which the option was granted.
- [F4]The option became exercisable in four equal installments beginning on January 21, 2015, which was the first anniversary of the date on which the option was granted.